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Abstract
Background: Chronic obstructive pulmonary disease and emphysema develops in 15% of ex-smokers despite sustained
quitting, while 10% are free of emphysema or severe lung obstruction. The cause of the incapacity of the immune system to
clear the inflammation in the first group remains unclear.
Methods and Findings: We searched genes that were protecting ex-smokers without emphysema, using microarrays on
portions of human lungs surgically removed; we found that loss of lung function in patients with chronic obstructive
pulmonary disease and emphysema was associated with a lower expression of CD46 and verified this finding by qRT-PCR
and flow cytometry. Also, there was a significant association among decreased CD46
+ cells with decreased CD4
+T cells,
apoptosis mediator CD95 and increased CD8
+T cells that were protecting patients without emphysema or severe chronic
obstructive pulmonary disease. CD46 not only regulates the production of T regulatory cells, which suppresses CD8
+T cell
proliferation, but also the complement cascade by degradation of C3b. These results were replicated in the murine smoking
model, which showed increased C5a (produced by C3b) that suppressed IL12 mediated bias to T helper 1 cells and elastin
co-precipitation with C3b, suggesting that elastin could be presented as an antigen. Thus, using ELISA from elastin peptides,
we verified that 43% of the patients with severe early onset of chronic obstructive pulmonary disease tested positive for IgG
to elastin in their serum compared to healthy controls.
Conclusions: These data suggest that higher expression of CD46 in the lungs of ex-smoker protects them from emphysema
and chronic obstructive pulmonary disease by clearing the inflammation impeding the proliferation of CD8
+ T cells and
necrosis, achieved by production of T regulatory cells and degradation of C3b; restraining the complement cascade favors
apoptosis over necrosis, protecting them from autoimmunity and chronic inflammation.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a complex
multi variable disease, with raged inflammation triggered mainly
by cigarette smoke; regardless of sustained quitting approximately
15% of the ex-smokers develop severe emphysema and COPD.
Conversely, 10% of the ex-smokers do not develop emphysema or
lung obstruction despite having the same smoking history; the
reason for the inability to clear the inflammation in the first group
is not well know [1]. The inflammation seen in patients with
COPD have an innate and adaptive nature, initially much of the
focus of the studies were into the innate response lead by the
proteases secreted by macrophages and neutrophils that destroyed
the extracellular matrix (ECM) [2]. Later was assessed the
presence of CD8
+ T cells indicating a role for the adaptive
response through release of granzymes and perforins that kill
epithelial cells [3]. After reports of CXCR3 positive T cells
indicating a T helper 1 (Th1) type of immune response [4] we
found CXCR3 on macrophages [5] and showed that cross-talk
among T cells and macrophages through the binding of interferon
gamma (INFc) inducible protein 10 (IP10), secreted by T cells, to
the CXCR3 receptor on macrophages macrophage-metallo-
protease 12 (MMP12) was induced, showing a feed forward loop
that destroyed the ECM through a non-antigenic cross talk [5].
The reason why this destructive mechanism is not suppressed after
the initial smoke injury is removed remains unclear. The
hypothesis that a sub-set of ex-smokers with COPD actually has
an autoimmune disease to elastin that impairs the inflammation
clearance remains debatable [6–9], although, there are recent
reports of IL17 producing T cells that also associated COPD and
autoimmunity [10–15]. In normal individuals autoreactive T cells
are eliminated in the thymus through a selection of those cells with
T cell receptors (TCR) that binds weakly to a self-antigens and
may induce anergy. However, there is an intrinsic mechanism that
eliminates T cells that strongly binds to self antigens, by up
regulation of FAS ligand (FASL) and its receptor CD95 which
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e18785activating the signaling pathway of caspase (Casp) 8 and
proteolysis leads to apoptosis. This is an important regulatory
mechanism against autoimmunity because mice and humans with
defects in the FAS pathway develop systemic autoimmunity
[16–18]. When a T cell with an autoreactive TCR that bind
strongly or weakly to self antigens has left the thymus there is an
extrinsic regulatory mechanism that involves the suppression of
these autoreactive T cells by T regulatory cells (Treg) to prevent
autoimmunity [17]. Tregs are CD4
+CD25
+T cells, they express
FOXP3, secrete IL10, suppress cytotoxic (Tc) and helper (Th1) T
cells. Tregs are produced by coupling of CD3 with CD46; they are
able to regulate the responses adaptive. CD46 not only regulates
the Treg production but also the innate response through
degradation of the complement 3b protein (C3b), which is
required for the cleavage of C5 to C5a, a potent chemoattractant
that forms the membrane attack complex (MAC) [19,21]. There is
evidence that Tregs are down regulated in patients with COPD;
however, its mechanism remains unknown [6]. The aim of this
study was to identify genes that protect ex-smokers from
developing end stage COPD/emphysema by clearing the
inflammation triggered by cigarette smoke after smoking cessation.
We identified CD46 as protective gene that plays a pivotal role
between the immune response adaptive and innate; down
regulation of CD46 was associated with CD4
+T cell depletion,
CD95 down regulation, and C3b accumulation with increased
C5a in the lung. All together these data indicates a key role of
CD46 in inflammation clearance and homeostasis of the immune
response.
Methods
Subjects
This was a multicenter effort to study eighty-seven subjects
(Table 1) with and with out COPD and emphysema, which were
recruited subsequent written informed consent signature; the
pertinent institutional review board for human studies approved
all protocols. These subjects were further subdivided in different
groups for microarray, flow cytometry or autoimmunity testing as
detailed bellow.
Microarray. Thirteen non-atopic ex-smokers enduring
medically necessary lung surgery, due to lung volume reduction
(LVRS) or small peripheral carcinoma, as detailed in Table 2,
were sequentially entered into the study to investigate their gene
expression pattern, after the initial insult has ceased, to assess
which genes are protecting ex-smoker without emphysema from
developing severe emphysema/obstruction: four subjects of age
78(6), were used as control (control group), which had no to mild
obstruction according to their pulmonary function test (PFT),
forced expiratory volume in one second (FEV1) percentage of
predicted, average (SD), 80(24) and no emphysema as shown by
their computed tomography (CT) scan; five patients of age 71(7)
with mild to moderate emphysema and COPD 65(15) FEV1%
(emphysema group); four patients age 65(5) with severe
emphysema and COPD (end-stage group) shown by a FEV1%
34(9) and high resolution computed tomography (HRCT), and/or
conventional CT scan performed as previously described [5] was
used to classify on the presence or the absence of centrilobular,
paraseptal or panlobular emphysema [22–24]. COPD was
diagnosed according to the criteria recommended by the NIH/
WHO workshop summery [25]. All subjects were recruited from
the surgical clinic at the Houston Veterans Affair Medical Center.
The patients had no history of allergy or asthma and had not
received oral/systemic or inhaled corticosteroids during the last six
months. At the time of study, all patients were free of acute
symptoms suggestive of upper or lower respiratory tract infection
in the 6 weeks preceding the study.
Autoimmunity to elastin. Forty-nine participants were
entered into this study, serum from twenty-one individuals were
chosen because of their early on set of COPD (EO-COPD) is likely
to be caused by an autoimmune disease; they had average age of
50(3) with severe emphysema and end-stage COPD as shown by
pulmonary function test (FEV1%) 21(5). Twenty-eight subjects
with matching age 49(11) and no obstruction/emphysema
according to their FEV1% 95(8) were used as control. All
participant had a smoking history of 50(3) pack per year (PPY) for
EO-COPD and 21(15) PPY for control, 18 of the EO-COPD and
14 of the control group were ex-smokers all with similar quitting
time (QT). Subjects were recruited from the Brigham and
Women’s Hospital clinic at the Longwood Medical Center,
Boston, MA, USA.
Lung tissue collection. Tissue from human peripheral lung
obtained at the time of the surgery from the furthest away region
of the lesion, it was separated in two fractions with the purpose to
obtain mRNA for gene expression study and live cells. One
fraction was placed in RNA-latter to preserve the tissue for
extraction of mRNA using RNeasy kit from QIAGEN. The
remaining tissue fraction was used to extract live cells for protein
quantification. The extracted mRNA was used for gene expression
detection with GeneChip technology and qRT-PCR was
performed on the same mRNA samples using validated Assay-
On-Demand primers and probes from A&B Applied Biosystems to
verify the microarray results on genes of interest on the same
patients included for microarray.
Gene chip of human lung tissue. RNA was extracted from
lung tissue using RNeasy kit from QIAGEN, according to
manufacturer’s recommended protocol and was used in microarray
analysis. We followed established protocols (Affymetrix; the M.D.
Anderson Cancer Center microarray core) to synthesize double
Table 1. Clinical and Demographic Characteristics of
Participants.
Control
(n=36)
Emphysema
(n=17)
End-Stage
(n=34)
Emphysema
a No Yes Yes
GOLD stage 0-1 3-2 4
LVRS
b (n) 12
f
Small peripheral Cancer (n) 9
f 17
f
Age (Average 6 SD) 65612 68645 6066
Percent FEV1
c (Average 6 SD) 84615 63615 2866*
Pack-years smoking
d
(Average 6 SD)
55637 60624 52617
Ex-smokers (n) 23 17 30
QT
e(Years) 9610 4661 1 611
aDetermined by Ct scan.
bLung Volume Reduction Surgery (LVRS).
cPercentage of Forced expiratory volume (FEV1) in one second is *significantly
different (p,0.05) for the end-stage group compared to the control group.
dPacks per years (PPY), quitting time (QT) and age values are similar among the
three groups.
eQuitting time: continue time without smoking since quitting.
f, The patients had no history of allergy or asthma and had not received oral/
systemic or inhaled corticosteroids during the last six months. At the time of
study, all patients were free of acute symptoms suggestive of upper or lower
respiratory tract infection in the 6 weeks preceding the study.
doi:10.1371/journal.pone.0018785.t001
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total of thirteen subjects were used in Affymetrix Human Genome
U133A Array (HG-U133A) [26].
Microarrays Data Analysis. Scanned GeneChip DAT files
were analyzed by the Gene Chip Analysis Suite Software
(Affymetrix) with global scaling to 1,000. Gene screening was
performed in Microsoft Excel; first by the p value of the signal for
each probe set, 22,284 in total and for each patient. Probes with p
values below 0.05 in the 13 patients were considered present and
named with a P. Probes with p-value(s) more than 0.05 were
considered absent and named with an A. To consider a gene absent
within a group it was required that at least 1 patient had p-value(s)
more than 0.05 in that particular gene and p-value(s) not more than
0.05forittobeincludedwithinthepresentgroup.Genessegregated
in this manner were further investigated using Pub Med database.
Cell Isolation from surgical lung specimens for Flow
cytometry. We used a combination of mechanical fragmentation,
enzyme digestion, and centrifugation procedures described previously
[22]. Total cell extracted were resuspended to a final working
concentration of 1610
7 cell/ml in RPMI for use in immune assays
and labeled with fluorescent dyes conjugated to anti-CD3, -CD14,
CD66, CD46 and CD95 antibodies monoclonal, purchased from BD
Biosciences Pharmingen (San Diego, California, United States), for
flow cytometry [5].
The patients population was classified as described above for
microarray test in control, emphysema and end-stage; we recruited
a total 38 patients, their lung function was for controls FEV1% of
80(18) (n=9), emphysema 63(15) (n=17), and end-stage 32(6)
(n=12), they had similar age 71(12), 68 (45), 65(8) respectively;
and similar smoking history 68(45), 60(24), 54(25) PPY, they were
all ex-smoker with similar quitting time 9(10), 4(6), 11(11) for
control, emphysema and end-stage respectively.
Mice
C57 mice were purchased from Jackson Laboratories (Bar
Harbor, ME). Age- and sex-matched WT mice were used as
controls. The Harvard Standing Committee for Animal Research
at Harvard University School of Public Health approved all
animal experiments. Transgenic mice deficient in C5aR and
CXCR3 were generated in the laboratory of Dr. Gerard.
Cigarette Smoke Exposure. WT mice 8–12 weeks of age
were exposed to four unfiltered cigarettes per day (University of
Kentucky), six days a week for one or four week for acute effect or
six months for chronic exposure according to standard procedures
[27].
Tissue Processing. The bronchoalveolar lavage (BAL) was
performed by the standard method previously described [28].
The lungs were lavaged four times with 1 ml PBS. Then, the left
lung was ligated and removed for western blot analysis. The inflated
lungs were fixed in 4% paraformaldehyde, serial mid-sagittal
sections in paraffin were obtained for immunohistochemistry and
morphometry [29].
Immunohistochemistry. analysis of CD46 was done using a
custom (rabbit anti-mouse) antibody from Prosci (Poway, CA, USA)
Table 2. Protective genes.
Microarray Results qRT-PCR Validation
a
Gene ID Official gene name Control
b Emphysema
b End-stage
c
D84105 Membrane cofactor protein (CD46) 12.061.0 9.060.5*
d 4.061*
NM_001228 Caspase 8, apoptosis-related cysteine protease (Casp8) 138.0645.0 27.065
{ 34.0610*
U12767 Nuclear receptor subfamily 4, group A, member 3 (NR4A3) 23.069.0 27.0615.0
{ 4.061
{
NM_001419 Embryonic lethal, abnormal vision, Drosophila Antigen like 1 (Hu antigen R)
AF074480 Cytidine monophosphate-N-acetylneuraminic acid hydroxylase
(CMP-N-Acetylneuraminate monooxygenase) (CMAH)
NM_005911 Methionine adenosyltransferase II, alpha (MATII)
BE870509 Hepatocyte growth factor receptor (HGFR)
AA918442 Insulin-degrading enzyme (IDE)
NM_006540 Nuclear receptor coactivator 2 (NRCO2)
NM_003619 Protease, serine, 12 (neurotrypsin, motopsin) (PRSS12)
M97935 Signal transducer and activator of transcription 1, 91 kDa (STAT1) 23.069.0 12.061.0 3.561.6
{
L38019 Inositol 1,4,5-triphosphate receptor, type 1 (IP3R1)
NM_021140 Ubiquitously transcribed tetratricopeptide repeat gene, X chrom.(UTX) 1.360.4 2.061.2 0.660.3
1
AF074000 Lectin, galactoside-binding, soluble, 8 (galectin 8)
NM_005734 Homeodomain interacting protein kinase 3 (HIPK3)
NM_024530 FOS-like antigen 2 (FOSL2)
AI638420 Chloride intracellular channel 4 (CLIC4)
BE963370 BCL2-associated transcription factor 1 (BCLAF1)
amRNA expression tested in the same participants by microarray and quantitative RT-PCR which had either
b lung resection for treatment of small peripheral cancer
(n=5); or
c lung volume reduction surgery for emphysema (non-cancer, n=4).
dValues are expressed as average 6 SD, P values are relative to control, calculated using two tailed T students test.
*,p ,0.0001;
{,p ,0.001;
{,p ,0.01;
1,p ,0.05.
doi:10.1371/journal.pone.0018785.t002
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Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA,
USA) in which 3,39-diaminobenzidine (DAB) was the chromogenic
substrate. Results are represented as the average count from ten
different high-powered fields per slide that have been corrected for
mm of alveolar wall.
Immunoprecipitation:. Two mg of whole lung protein homog-
enate were pre-cleared with 20 ml of protein A (Zymed, San
Francisco, CA), centrifuged to eliminate non-specific binding. The
supernatant was treated with 20 ml of anti C3b from HyCult
Biotechnology (Canton, MA) and incubated for 2 hrs at 4uC.
Twenty ml of protein A were added and incubated overnight on a
rocker at 4uC. The supernatant was separated by Western blot,
performed according to manufacturer instructions. Mouse mono-
clonal anti-C3b antibody from Hycult Canton, MA was used at
1:200 dilutions and developed with anti-mouse HRP-conjugated
antibody (Amersham, Piscataway, NJ, USA). Elastin co-localiza-
tion was performed stripping the membrane with western re-probe
solution and re-probing for elastin with BA4 antibody [30].
Peptide ELISA. Costume elastin peptides of 15 amino acids
in length (Open Biosystems, Huntsville, AL) were plated at a
concentration of 100 mg/ml with carbonate buffer pH 9.4 from a
solution kit from BD (OptEIA cat 5505534, San Diego. CA).
Human serum, 100 ml diluted 1:100 was used to detect the
presence of anti-elastin IgG. Samples were incubated 24 hr at 4uC
before washes were performed. Colorimetric measurement was
performed using alkaline phosphatase reaction; the optical density
was measured at 480 nm.
Statistics. Data are expressed as the mean value 6 SD unless
otherwise indicated. Statistical significance was determined using
Mann-Whitney no parametric test, two tails, for human data
comparison, and student’s t-test (two-tailed distribution with a two-
sample equal variance) for animal work.
Results
There are 18 protective genes expressed in healthy
ex-smokers
From the gene array analysis of ex-smokers with and without
emphysema/COPD (Table 1) we identified genetic deficiencies
that may underlie the Treg cell deficiency and chronic
inflammation in COPD, and/or elastin-specific autoimmunity,
Figure 1. Quantification of CD46 levels. (A) Forward and side scatter plot of lung cells. Circles show the lymphocyte, macrophages and
neutrophil populations. To the right a single color histograms showing expression of receptor CD46 from representative control, emphysema and
end-stage participants. Pooled data from all participants (control, n=4; emphysema, n=4, end-stage n=5) showing percent (median6SD) of total
lung neutrophils, and macrophages expressing CD46; Cumulative values for lymphocytes showed a significative decrease (control, n=6; emphysema,
n=7, end-stage n=6, p,0.05) more patient were included with the same lung characteristics. (B) Gene expression of Casp 8, on the same patients,
determined by qRT-PCR (median6SD) on emphysema patients with (n=5) and without cancer (n=4) shows no different expression level due to
cancer away from the emphysemic region (p=1). Mann-Whitney test was used to determine significant difference.
doi:10.1371/journal.pone.0018785.g001
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only in control patients and not in diseased patients; we found 18
gene products that we called protective genes, listed in Table 2,
and verified 5 of them by quantitative RT-PCR. Defective
expression or polymorphism in these genes (Table 2) may be a
predisposing factor for chronic inflammation that leads to COPD.
CD46 depletion accumulates C3b bond to elastin on lung
tissue
The first gene we focused on was CD46 because it plays a
pivotal role in the crosstalk between the innate and adaptive
immune responses, the over-expression of CD46 in controls was
verified at the mRNA level using qRT-PCR and at the protein
level by flow cytometry (Table 2). Since T cells were our main
interest we added more patients with the same characteristics of
the microarray patients (Table 1) to verify differences at the
protein level; the results show a significantly higher expression of
CD46 on T cells of control patients, without variation on
macrophages or neutrophils (Fig. 1A), this data is further
supported by the in vivo experiments. We also verified that the
gene expression differences were due to emphysema and not
cancer since control patients had cancer while emphysema
patients had cancer or lung volume reduction (LVRS), to that
end we segregated the emphysema patients in cancer (n=5) and
no cancer (n=4) and checked their gene expression level of Casp8
by qRT-PCR to asses that there was not significant differences in
the cell survival among those two subset based on the co-founding
disease (p=1, Fig. 1B). Using the smoke-exposed murine model of
COPD, we observed a significant decrease in CD46 expression in
the lung (Fig. 2A) that was accompanied by significantly increased
accumulation of C3b on the lung tissue, which co-precipitated
with elastin (Fig. 2B).
Cigarette smoke activates the complement pathway that
suppresses Th1 cells biases
Since C3b is required for the cleavage of C5 into C5a and C5b
we quantified the protein down-stream, C5a. Furthermore, the
inflammation caused by cigarette smoke (Fig. 3A) in the acute
stage (1 week) resulted in a significant increase of IL12 secretion,
which biased the immune system to Th1 and was suppressed by
C5a up-regulation at the 4
th week (Fig. 3B) of inflammation but
this response was significantly impeded in C5aR knockout mice at
1 and 4 weeks of cigarette exposure (p=0.03, n=3 and n=5 for
Wt) (Fig. 3A). Mice knockout in CXCR3 at the 4
th week fails to
sustain secretion of both the pro-inflammatory cytokine IL12
(p=0.06, n=3) and C5a (Fig. 3D), while C5aR-deficient mice
only demonstrate decreased IL12 secretion. After the initial bias to
Th1 occurred these cells secrete IP10 that binds to the CXCR3
receptor on macrophages inducing MMP12, and secretion of
perforin and granzymes from CD8
+ T cells that kill epithelial cells
[28] releasing large amounts of elastin and causing cell death.
Decreased expression of CD95 indicates failure to
eliminate Tc by Treg
Since memory Treg are created by CD46 coupling with CD3
that suppresses Tc (CD8
+ T cells), which are eliminated via
apoptosis involving Casp8 [31], a protective gene (Table 2), this
forms a complex with Fas-associated death domain (FADD)
FADD and the FasL receptor (CD95) [32]. In addition, other 5
protective genes regulate CD95 (Fig. 4A), Cytochrome C (Cyto C),
released by Chloride intracellular channel 4 (CLIC4), is a positive
regulator of CD95 that mediates activation of Casp 8 and
apoptosis (Fig. 4A) [33]. Homeodomain interacting protein kinase
3 (HIPK3) phosphorilates CD95 [32] and HuR stabilizes CD95
Figure 2. Inflammation in the murine smoking model. (A) Increased expression of CD46 in the lung tissue of no smoker mice compared to
smoke exposed mice determined by IHC, arrow heads, and by western western blot on lung tissue homogenates of control mice or smoke-exposed
mice (p=0.02, n=4, n=4). (B) Increased deposition of C3b on lung tissue of control mice (n=3) compared to smoke- exposed mice at 4 and 24
weeks (n=3) determined by Western blot. Middle plot, immunoprecipitation of C3b from lung homogenate shows a significant increase of C3b
deposition upon smoke exposure (p=0.05). Elastin was stained and detected after stripping the membrane, showing significant increased co-
precipitation with C3b (p=0.01). Student t-test two tails was used to compare both groups; values in the plots represent average 6 SD.
doi:10.1371/journal.pone.0018785.g002
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activated by proliferation [18] and hepatocyte growth factor
receptor (HFGR) sequesters CD95 upon binding to its ligand [35],
and both negatively regulates CD95 (Fig. 4A). Thus, we also
verified a significant decreased of CD95 that was associated with
the CD46 down regulation (Fig. 4B), which has an important role
in the down-regulation of immune responses; since severe
autoimmunity is developed in human and mice with deficiency
in the Fas pathway [16,18]. CD46 coupling with CD3 activates
the transcription factor ubiquitously transcribed tetratricopeptide
(UTX) [36] that interacts with signal transducer and activator of
transcription 1 (STAT1) [37–39] both translocate to the nucleus to
activate proliferation (Table 2). T cell receptor activates Bcl-2,
which inhibits cytochrome C (Cyto C) [33] and cell death (Fig 4A)
[40]. Thus, we inferred the pattern of T cells proliferation with
disease progression through the analysis of the total lymphocytes in
lung parenchyma; we verified that the increment in CD8
+ T cells
was at expenses of the CD4
+ T cells population (Fig. 4 B) that
directly correlated with the lung function decay (CD4/CD8 vs
FEV1, Fig. 4B, bottom right corner). Most importantly, a positive
association among CD4
+ T cell depletion and CD46 reduction
was also proven to be significantly linear (r=0.896, p=0.006,
Fig. 4C) indicating that selective depletion of Tregs with disease
progression was associated with down regulation of CD46.
IgG to elastin is present in serum of patient with early
onset of COPD
We thought that if elastin peptides were bound to C3b because
they were presented as an auto-antigen, activating T cells, then we
should also find IgG to elastin in the serum of patients that
manifested early on-set of COPD (EO-COPD), we included for
this study a total of 49 participants, 21 EO-COPD and compared
them to 28 control, normal subjects. We identified a region of the
elastin protein that had more immunogenic properties; the
different level of IgG binding to this region among the responders,
which were classified as such if their OD was above the threshold
set at the highest background, was of (9,9) and no responders
(19,12), for control and EO-COPD respectively. EO-COPD group
showed a significantly higher (86%) titer of IgG to elastin then
normal controls (p=0.0308 determined by Mann-Whitney test,
Fig. 4D). According to these results the sensitivity of the ELISA
test used is 43% and the specificity 68%.
Discussion
In this study we searched for genes that protect ex-smoker from
developing severe emphysema and COPD. We found that ex-
smokers without emphysema had higher expression of CD46 in
their lungs compared to emphysema/COPD patients, that also
occurred in vivo in the murine smoking model of COPD where
CD46 down regulation was accompanied with accumulation of
C3b co-precipitated with elastin and increased C5a which in
return suppressed secretion of IL12, from macrophages, stimulat-
ed by the cigarette smoke. In contrast, CD46 down regulation was
associated with decreased FEV1%, decreased expression of CD95
and CD4
+ T cell depletion concomitantly with CD8
+T cells
increase in lung parenchyma of emphysema/COPD patients. The
proliferation of CD8
+T may be due to elastin that is being
presented as an auto-antigen, since 43% of COPD patients with
early onset of the disease had IgG binding to elastin in their serum.
It is remarkable that CD46 depletion rather then ubiquitous was
on T cells, and replicated in the murine smoking model which
ensures that this effect rather then being mediated by cancer or
viral infections is due to cigarette smoke itself, reducing the
variables to oxidative stress and free radicals effect on CD46. Free
radicals may react in random manner with the cell surface proteins
leaving them un-functional or even cleaving them, depletion of this
receptor may be underlying the T cell dysregulation and increased
cells death associated with cigarette smoke; nevertheless after
smoke cessation normal individuals up-regulate CD46 and recover
the immunological homeostasis, even some of their lung function.
However, the fact that in patients with severe COPD there is
persistent down regulation of CD46 mRNA after the noxious
irritant has been removed, indicates dysregulation at the
transcriptional level, perhaps due to polymorphisms or latent
viral infections such as measles or adenovirus [41].
It was expected an accumulation of C3b, in COPD, due to its
co-dependence on CD46 for its degradation but the novelty of the
co-precipitation of elastin with C3b, seen in humans (data not
shown) and mice suggested that elastin might be presented as an
antigen. However, the presence of IgG binding to elastin in only
43% of the early onset COPD indicates either the existence of
other antigen that may be causing the remaining 57% EO-COPD
Figure 3. Kinetic of the inflammation in murine smoking
model. Secretion of IL-12, C5a and IL-10, measured in mice
bronchoalveolar lavage (BAL) of wild type (-&-Wt), C5aR knockout
(-N-C5ar2/2) and CXCR3 knockout (-#-CXCR32/2) mice exposed at
different times to cigarette smoke determined in Wt, C5ar2/2 and
CXCR32/2. (A) Top plot show significantly less IL12 (average 6 SD)
secretion in C5aR 2/2 (*, p,0.001, n=3) compared to Wt, while (B)
CXCR32/2 shows significantly decrease C5a secretion (**, p=0.02,
n=3) at 4 weeks smoke and (C) decreased IL10 (1, p=0.03, and n=3)
relative to Wt (n=6). P values were calculated using T student test, two
tails.
doi:10.1371/journal.pone.0018785.g003
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reports in this matter [6–9], it is possible that a abridged sensibility
of the tests and/or divergent COPD variants tested may cause
dispersion in the results.
T cells ratios vary significantly with the progression of the
disease showing an intersection point when the number of CD8
+T
cells reach the same number then CD4
+T cells (30%) in patients
with 60% of FEV1 predicted, from this point on, there is a steep
loss of CD4
+T cells compared to CD8
+T proliferation; supporting
the concept of an extrinsic dysregulation of autoreactives T cells
due to loss of Tregs when patients enter in the stages 3 and 4 of
GOLD with severe COPD/emphysema [6]. Simultaneously,
CD46 down regulation falls bellow 40% suggesting an increased
participation of the complement pathway through configuration of
MAC and cell lyses. Increased cells lyses is indirectly associated,
through CD46, to reduced apoptosis, as shown by the decay of
Figure 4. Molecular cross-talk of the protective genes. (A) CD46 coupling with CD3 activates the transcription factor ubiquitously transcribed
tetratricopeptide (UTX), which interacts with signal transducer and activator of transcription 1 (STAT1) both translocate to the nucleus to activate
proliferation of CD4
+T cells. T cell receptor activates Bcl-2 that inhibits cytochrome C (Cyto C) released by chloride intracellular channel 4 (CLIC4),
which positively regulates Fas Ligand receptor (CD95) mediated activation of Caspase 8 (Casp 8) and apoptosis. Homeodomain interacting protein
kinase 3 (HIPK3) phophorilates CD95, and HuR stabilizes CD95 mRNA also positively regulates it. While 2 negative regulators of CD95 are methionine
adenosyl transferase II, alpha (MATII) and hepatocyte growth factor receptor (HFGR). Red font signifies protective gene, black arrow apoptosis
activation, black bold arrow apoptosis inhibition. Red arrow, proliferation pathway. Red proteins are kinases; blue, transcription factors; light brown,
cell surface receptors. (B) Total CD46 expression on the surface of lung cells of patients (n=14) significantly correlates with their FEV1% in a linear
regression using minimum square approximation, with a coefficient r=0.563 and a goodness of fit p=0.036. The FasL receptor, CD95, protein
expression on the same patients, also, positively correlates with FEV1% with an r=0.711 and a goodness of fit p=0.006. There is a significative linear
association between cells surface proteins expression, CD46
+ and CD95
+ (r=0.666, p=0.012). Right top plot, total lung lymphocytes CD4
+ plus CD8
+
has a constant number in the lung parenchyma despite their lung FEV1% change with disease progression (r=0.107, p=0.6332, n=22) although
there is a significant change in the number of CD4
+ and CD8
+ T cells. Right middle plot, in the same patients group, CD4
+T cells (black circles)
correlates directly with the FEV1% (r=0.549, slope=0.24, p=0.008, n=22), conversely CD8
+ T cells (red circles) inversely correlates with FEV1%
increasing its number with disease progression (r=0.480, slope =20.329, p=0.024). Bottom right plot shows a direct correlation between FEV1%
and depletion of CD4
+ with increment of CD8
+ T cells (slope=8.4, r=0.726, p=0.0002). (C) There is a remarkable association among CD46
+
decrement and CD4
+/CD8
+ ratio of T cells, r=0.896 p=0.006, n=7. (D) Increased IgG to elastin in early-onset COPD (EO-COPD) patients, relative to
normal controls, tested in n=21 and n=28, respectively, plot represents the patients that give signal above the threshold n=9 for both EO-COPD
and control with a significant increased in the diseased group p=0.038, determined by Mann-Whitney test, values represent median 6 SD.
doi:10.1371/journal.pone.0018785.g004
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reinforcing the hypothesis that these patients will be at risk to
develop autoimmunity also due to intrinsic dysregulation in the
mechanism responsible for elimination of auto reactive T cells
which favors necrosis over apoptosis.
From the kinetic of the inflammatory process seen in the animal
model we learn that acute exposure to cigarette smoke initially
triggers the Th1 bias inducing IL12 from macrophages [42],
which is repressed later by the complement system with the
increase of C5a [43,44]. The early induction of IL12 indicates an
effect of cigarette smoke itself on macrophages in the bias towards
Th1 which is in agreement with previous reports of INFc secreting
T cells in the lung parenchyma [5,45–47]. The production of IL12
and IL17 are mutually exclusive [48]; this discrepancy with recent
reports of IL17 production in human COPD [49] may be because
we are using BAL samples from mice, airway and parenchyma,
where high amount of IL12 makes it unlikely to have
simultaneously IL17 production, unless it is confined to a specific
microenvironment of the airways that would account for a small
amount of the total cytokines produced in the whole lung,
nevertheless, future IL17 testing will shed light on this matter.
CXCR3 receptor is thought to be a marker of Th1 bias marker;
mice knockout in this receptor show incapacity to mount a full
immune response showed by the fact that the secretion of IL12
and C5a are deficiently produced at the 4
th week indicating a key
role of CXCR3 in disease progression, which turns it an
interesting candidate for preventive treatment.
In summary, CD46 plays a protective role against emphysema/
COPD by restraining the CD8
+T cells proliferation and the
complement cascade through production of Tregs that regulates
the ratios of CD4
+/CD8
+ T cells and simultaneously regulating
C3b deposition favoring apoptosis over necrosis, thus, protecting
this subjects from autoimmunity and chronic inflammation.
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